Impulse control, an executive process that restrains inappropriate actions, is impaired in numerous psychiatric conditions. This thesis reports three experiments that utilized a novel animal model of impulse control, the response inhibition (RI) task, to examine the substrates that underlie learning this task. In the first experiment, rats were trained to withhold responding on the RI task, and then euthanized for electrophysiological testing. Training in the RI task increased the AMPA/NMDA ratio at the synapses of pyramidal neurons in the prelimbic, but not infralimbic, region of the medial prefrontal cortex. This enhancement paralleled performance as subjects underwent acquisition and extinction of the inhibitory response. AMPA/NMDA was elevated only in neurons that project to the ventral striatum. Thus, this experiment identified a synaptic correlate of impulse control. In the second experiment, a separate group of rats were trained in the RI task prior to electrophysiological testing. Training in the RI task produced a decrease in membrane excitability in prelimbic, but not infralimbic, neurons as measured by maximal spiking evoked in response to increasing current injection. Importantly, this decrease was strongly correlated with successful inhibition in the task. Fortuitously, subjects trained in an operant control condition showed elevated infralimbic, but not prelimbic, excitability, which was produced by learning an anticipatory signal that predicted imminent reward availability. These experiments revealed two cellular correlates of performance, corresponding to learning two different associations under distinct task conditions. In the final experiment, rats were trained on the RI task under three conditions: Short (4-s), long (60-s), or unpredictable (1-s to 60-s) premature phases. These conditions produced distinct errors on the RI task. Interestingly, amphetamine increased premature responding in the short and long conditions, but decreased premature responding in the unpredictable condition. This dissociation may arise from interactions between amphetamine and underlying cognitive processes, such as attention, timing, and conditioned avoidance. In summary, this thesis showed that learning to inhibit a response produces distinct synaptic, cellular, and pharmacological changes. It is hoped that these advances will provide a starting point for future therapeutic interventions of disorders of impulse control. / Thesis (Ph.D, Neuroscience Studies) -- Queen's University, 2011-07-11 09:44:54.815

Repeated exposure to amphetamine (AMPH) induces sensitization to its behavioral-activating effects. The development of sensitization depends on (1) the direct actions of AMPH in the ventral tegmental area (VTA), the cell body region of the mesocorticolimbic DA system, and (2) AMPH-induced glutamatergic neurotransmission in this region. Moreover, sensitization is accompanied by morphological changes in mesocorticolimbic DA circuitry. During development, the DA system is organized, at least in part, by the netrin-1 family of guidance cues. Both netrin-1 and its DCC and UNC-5 receptors continue to be expressed in the mesocorticolimbic DA system of the adult brain. Importantly, netrin-1 receptor deficient mice do not develop sensitization to AMPH, implicating an involvement of netrin-1 signaling in AMPH-induced plasticity of the DA system. To explore this possibility, adult rats were pretreated with repeated AMPH or saline, and DCC and UNC-5 receptor expression was examined in DA cell body and terminal regions using western blot. Striking AMPH-induced increases in the expression of DCC and UNC-5 were observed in the VTA only. Remarkably, these changes depended on NMDA-mediated glutamatergic neurotransmission. This is the first demonstration that repeated AMPH pretreatment regulates netrin-1 receptor expression in the adult brain and suggests that netrin-1 receptor regulation may be involved in the development of AMPH-induced sensitization.

Adult rats produce two main types of ultrasonic vocalizations (USVs), occurring at 22 and 50 kHz USVs. These calls are associated with aversive and rewarding stimuli, respectively. The neural mechanism of amphetamine-induced calling was examined in lesion and antagonist studies. We also tested whether amphetamine-induced 50 kHz USVs could predict individual differences in intravenous self-administration or conditioned place preference behavior. Further experiments examined whether 50 kHz USVs could be evoked by amphetamine-conditioned sensory stimuli and by rewarding electrical brain stimulation. Overall, our experimental findings: (1) identify certain experimental conditions that increase amphetamine-induced 50 kHz calling, (2) provide evidence that these calls may be dependent on mesolimbic dopaminergic transmission, (3) relate individual differences in 50 kHz vocalizing to other behavioural measures of drug reward, and (4) show that in some situations, 50 kHz calls reflect anticipation of expected rewards.

Translational research suggests that agonist replacement may be a viable treatment approach for managing methamphetamine dependence. This study sought to determine the effects of d-amphetamine maintenance on methamphetamine self-administration in stimulant using participants. A cognitive battery was used to determine the performance effects of methamphetamine alone and during d-amphetamine maintenance. During each maintenance condition, participants first sampled a dose of intranasal methamphetamine then had the opportunity to respond on a progressive ratio task to earn portions of the sampled dose. Subject-rated drug-effect and physiological measures were completed prior to and after sampling methamphetamine. Methamphetamine was self-administered as function of dose regardless of the maintenance condition. Methamphetamine produced prototypical subject-rated effects, some of which were attenuated by d-amphetamine maintenance. Methamphetamine was well tolerated during d-amphetamine maintenance and no adverse events occurred. The self-administration results are concordant with those of clinical trials that show d-amphetamine did not reduce methamphetamine use. Generally, there was no difference in cognitive performance after methamphetamine administration during both placebo and d-amphetamine maintenance. Overall d-amphetamine does not appear to be a viable treatment for preventing methamphetamine relapse, but translational literature suggests that other agonist medications or the combination of pharmacotherapy and behavioral therapies may be effective.

Maternal stress during the perinatal period has been linked to attention and behavioral problems and increased adrenocortical activity in children. Underlying this relationship is thought to be exposure to excessive glucocorticoids during development. The aim of this set of studies was to determine the effects of chronic maternal stress (CMS) during the perinatal period on behaviour and endocrine function in male and female guinea pig offspring at the juvenile and adult life stage. Environmental enrichment was investigated as a potential therapeutic tool to reverse changes induced by CMS. Pregnant guinea pigs were exposed to a sequence of stressors every other day over the second half of gestation until weaning on postnatal day 25. Offspring were tested for ambulatory activity, attention, cognitive function, sex-steroid levels and adrenocortical function. One cohort of animals were housed in an enriched environment, the remaining offspring were housed in standard conditions. A separate cohort was administered amphetamine (1 mg/kg) prior to behavioural testing to determine influence of CMS on dopaminergic function. Juvenile male and female offspring of mothers exposed to stress exhibited increased basal and decreased stress-induced salivary cortisol, and male offspring displayed reduced activity and a phase shift in their circadian rhythm of activity. Adult male offspring of CMS mothers exhibited increased activity in a novel environment and decreased activity in a familiar environment. Female adult offspring of CMS mothers exhibited reduced attention and increased activity in a novel environment. Enrichment acted independently of CMS, increasing plasma testosterone and attention in adult male offspring and reducing the adrenocortical response to stress and decreasing attention and activity in female offspring. Amphetamine decreased activity in a novel environment and increased activity in a familiar environment in both sexes, regardless of age or maternal treatment. Amphetamine improved attention in juvenile and adult males. The current studies demonstrated a strong effect of CMS on behaviour in juvenile and adult offspring. Enrichment was not effective for attenuating the effects of CMS. These studies clearly demonstrate behavioural changes as a result of CMS emerge over the lifetime of the offspring and have begun to uncover the underlying mechanisms of programming.

Maternal stress during the perinatal period has been linked to attention and behavioral problems and increased adrenocortical activity in children. Underlying this relationship is thought to be exposure to excessive glucocorticoids during development. The aim of this set of studies was to determine the effects of chronic maternal stress (CMS) during the perinatal period on behaviour and endocrine function in male and female guinea pig offspring at the juvenile and adult life stage. Environmental enrichment was investigated as a potential therapeutic tool to reverse changes induced by CMS. Pregnant guinea pigs were exposed to a sequence of stressors every other day over the second half of gestation until weaning on postnatal day 25. Offspring were tested for ambulatory activity, attention, cognitive function, sex-steroid levels and adrenocortical function. One cohort of animals were housed in an enriched environment, the remaining offspring were housed in standard conditions. A separate cohort was administered amphetamine (1 mg/kg) prior to behavioural testing to determine influence of CMS on dopaminergic function. Juvenile male and female offspring of mothers exposed to stress exhibited increased basal and decreased stress-induced salivary cortisol, and male offspring displayed reduced activity and a phase shift in their circadian rhythm of activity. Adult male offspring of CMS mothers exhibited increased activity in a novel environment and decreased activity in a familiar environment. Female adult offspring of CMS mothers exhibited reduced attention and increased activity in a novel environment. Enrichment acted independently of CMS, increasing plasma testosterone and attention in adult male offspring and reducing the adrenocortical response to stress and decreasing attention and activity in female offspring. Amphetamine decreased activity in a novel environment and increased activity in a familiar environment in both sexes, regardless of age or maternal treatment. Amphetamine improved attention in juvenile and adult males. The current studies demonstrated a strong effect of CMS on behaviour in juvenile and adult offspring. Enrichment was not effective for attenuating the effects of CMS. These studies clearly demonstrate behavioural changes as a result of CMS emerge over the lifetime of the offspring and have begun to uncover the underlying mechanisms of programming.

Epidemiological studies indicate that maternal vitamin D deficiency may be a candidate developmental risk factor for schizophrenia. For example, people born in winter/spring, urban environments and dark-skinned individuals whose parents migrated to cooler climates are all at increased risk of developing schizophrenia later in life. The biological plausibility that a low prenatal level of vitamin D has an adverse impact on the developing brain has been studied using a developmental vitamin D (DVD) deficient rat model. These animals display molecular and anatomical abnormalities in brain development and alterations in behaviour as adults. Compared with control rats, neonatal DVD-deficient rat brains are different in shape; displaying a thinner cortex and larger lateral ventricles. Moreover, the brains appear to be less differentiated. At adulthood, DVD-deficient rats show an enhanced sensitivity to novelty-, antipsychotic- and psychomimetic- induced locomotion. These observations have lead to the hypothesis that dopamine and/or glutamate neurotransmission may be altered in DVD-deficient rats. Thus, the main aim of this thesis was to further characterise the dopamine and glutamate neurotransmitter systems in DVD-deficient rats. DVD-deficiency resulted in sex and age specific changes in dopamine signalling. At birth, DVD-deficient rats showed altered dopamine metabolism in the forebrain providing the first report of altered dopamine function after DVD-deficiency. Female DVD-deficient rats displayed a post-adolescent (at 3 months of age) enhanced response to amphetamine-induced locomotion. Accompanying this behavioural sensitivity were decreased levels of dopamine 1 and 2 receptor density in the nucleus accumbens. The altered behaviour in female DVD-deficient rats was not associated with increased dopamine release in the prefrontal cortex, caudate putamen or nucleus accumbens. Although a similar increase in the behavioural sensitivity to amphetamine was not observed in male DVD-deficient adult rats, increases in the density of the dopamine transporter were observed in the caudate putamen and nucleus accumbens. However, when examined at a mature adult age (6 months) neither the enhanced response to amphetamine, receptor or transporter changes persisted. These results suggest that after puberty a transient change in dopamine receptor signalling manifests as an altered response to amphetamine under certain environmental and experimental conditions. Glutamate signalling was probed with the N-methyl-D-aspartate receptor antagonist MK-801. Adult male DVD-deficient rats showed an enhanced locomotor response to MK-801 and this persisted when examined at a mature adult age. Female DVD-deficient rats showed an enhanced response but this was only observed at the mature adult age examined. No behavioral differences were observed prior to adolescence. This behavioural sensitivity did not appear to be due to altered dopamine release after MK-801 in the prefrontal cortex and caudate putamen. Taken together, male DVD-deficient rats develop a locomotor sensitivity to MK-801 at an earlier age than DVD-deficient females. This behavioural alteration is not associated with altered dopamine function. The combined results from the studies in this thesis present a complex phenotype that suggests altered dopamine and glutamate interactions in DVD-deficient rats that are dynamic; demonstrating both age and sex specific traits. I speculate that the development of these behavioural and neurochemical alterations in DVD-deficient rats follows a similar temporal profile to the symptomology observed in schizophrenia patients. Both behavioural sensitivities to amphetamine and MK-801 are observed in schizophrenia in addition to a delayed onset of symptoms in females. This provides further support for a role of vitamin D in the developing brain and suggests that a transient deficiency can result in long-term behavioural and neurochemical alterations. Together this suggests that the DVD-deficient rat model may be an informative model for exploring the developmental vitamin D deficiency hypothesis of schizophrenia.

Diss. (sammanfattning) Stockholm : Karolinska institutet, 2007. / Härtill 4 uppsatser.

Konstanz, Univ., Diss., 2006.

Lisdexanfetamina (LDX) é um pró-fármaco estimulante de longa duração indicado para o tratamento dos sintomas do transtorno do déficit de atenção e hiperatividade e do transtorno da compulsão alimentar periódica. A hidrólise da ligação amida da LDX ocorre in vivo liberando a molécula terapeuticamente ativa d-anfetamina (d-ANF) e o aminoácido l-lisina. Visto que a LDX se biotransforma à d-ANF – um potente estimulante do sistema nervoso central com destaque tanto na clínica quanto na toxicologia – existe potencial para uso inadequado, abuso e desvio para fins não terapêuticos. Nos laboratórios de toxicologia, amostras biológicas com resultados positivos para anfetamina (ANF) são um desafio, uma vez que alguns testes toxicológicos podem detectar ANF devido à utilização de alguns medicamentos, dificultando a sua interpretação. Assim, são necessários métodos bioanalíticos eficientes aliados ao conhecimento farmacocinético, que permite a verificação da possibilidade de detecção, a estimativa da janela de detecção e as concentrações que podem ser alcançadas em diferentes matrizes biológicas. Dessa forma, neste trabalho, foram desenvolvidos métodos bioanalíticos para quantificação simultânea da LDX e de seu produto de biotransformação, a ANF, nas matrizes biológicas fluido oral, plasma e urina utilizando a cromatografia líquida acoplada a detector de massas sequencial (CL-EM/EM). A preparação de amostra é simples, utilizando a precipitação de proteínas para o plasma, com pouca quantidade de solvente orgânico, a diluição para o fluido oral e a filtração para urina, ambas com nenhuma quantidade de solvente orgânico. As curvas de calibração utilizando o padrão interno ANF deuterada apresentaram linearidade entre 1 e 128 ng/mL para o fluido oral e o plasma e entre 4 e 256 ng/mL para a urina. A menor concentração das curvas de calibração é igual ao limite inferior de quantificação. Precisão e exatidão intra e interdia ficaram dentro dos limites de ± 15% para os controles e ± 20% para o limite de quantificação. Os métodos foram seletivos e sem efeito residual, porém apresentaram um leve efeito matriz, frequentemente encontrado em métodos de CL-EM/EM. O método foi aplicado para análise das amostras do estudo farmacocinético da LDX e ANF nas matrizes biológicas fluido oral, plasma e urina após administração oral de LDX. Seis voluntários do sexo masculino coletaram amostras de fluido oral e plasma em tempos pré-determinados durante 72 horas e amostras de urina em intervalos pré-determinados durante 120 horas. Os dados foram avaliados de maneira não-compartimental e compartimental. Considerando a análise não-compartimental, a concentração máxima média da d-ANF foi quase seis vezes inferior no plasma em relação ao fluido oral e ocorreu em 3,8 e 4 horas, respectivamente, após a administração oral. A LDX atingiu a concentração máxima no plasma e no fluido oral em 1,2 e 1,8 horas após a administração oral, respectivamente, com um valor médio de pico de concentração quase duas vezes mais elevado no plasma em comparação com o fluido oral. A eliminação da d-ANF a partir do plasma e a partir do fluido oral foi semelhante, porém para LDX a eliminação a partir do fluido oral foi mais lenta, mesmo com concentrações mais baixas do que no plasma. A detecção da d-ANF ocorreu até 48-72 horas no plasma e fluido oral e até 120 horas em urina. Já para a LDX, a detecção ocorreu até 3, 5 e 12 horas no plasma, fluido oral e urina, respectivamente. LDX intacta e d-ANF foram detectadas nas três matrizes avaliadas. Na análise compartimental, o melhor ajuste de modelo foi observado para 1 compartimento para ambos os analitos tanto no plasma quanto no fluido oral. Houve uma correlação entre as concentrações do fluido oral e do plasma para d-ANF e entre as proporções de LDX intacta/d-ANF pelo tempo no plasma e no fluido oral. O método analítico desenvolvido pode ser aplicado em diferentes áreas do conhecimento a fim de certificar os resultados de uma análise de triagem positiva para ANF. Porém, para interpretação das situações tanto de triagem quanto de confirmação é necessário aliar o conhecimento farmacocinético gerado no trabalho, que demonstra se há a possibilidade de detecção na matriz analisada e por quanto tempo após a administração da LDX. Isto auxilia na diferenciação do uso de outros medicamentos derivados da ANF e do uso ilegal, para que as devidas providências legais e de manejos clínicos de tratamento e controle de dependência sejam tomadas quando necessário. / Lisdexamfetamine (LDX) is a long-acting prodrug stimulant indicated for the treatment of attention-deficit/hyperactivity disorder and binge-eating disorder symptoms. In vivo hydrolysis of lisdexamfetamine amide bond releases the therapeutically active d-amphetamine (d-AMPH) and the amino acid l-lysine. Since LDX biotransformation gives rise to d-AMPH - a potent stimulant of the central nervous system that stands out in clinical and toxicology - there is potential for misuse, abuse and diversion for non-therapeutic purposes. In laboratories of toxicology, biological samples with positive results for amphetamine (AMPH) are a challenge, since some toxicological tests can detect AMPH due to the use of some medications hindering the interpretation. Therefore, we need efficient bioanalytical methods combined with the pharmacokinetic knowledge, which allows to verify the possibility of detection, to assess the detection window and the concentrations that can be reached in different biological matrices. Hence, bioanalytical methods were developed for simultaneous quantification of LDX and its main biotransformation product AMPH in the biological matrices oral fluid, plasma and urine by liquid chromatography-mass spectrometry (LC-MS/MS). The sample preparation is simple, using protein precipitation for plasma, with a small amount of organic solvent, dilution for oral fluid and filtration to urine, both with no amount of organic solvent. Calibration curves using deuterated AMPH internal standard showed linearity between 1 and 128 ng/mL for oral fluid and plasma, and between 4 and 256 ng/mL for urine. The lowest concentration of the calibration curve is the lower limit of quantification. Intra and interday precision and accuracy were within the limits of ± 15% for controls and ± 20% for the limit of quantification. The methods were selective and no carry-over was observed, however with some matrix effect, often found in LC-MS/MS methods. The method was applied to analyze samples from LDX and AMPH pharmacokinetics study in the biological matrices oral fluid, plasma and urine following oral administration of LDX. Six male volunteers collected oral fluid and plasma samples at predetermined times during 72 hours and urine samples at pre-determined intervals during 120 hours. Data were evaluated through non-compartmental and compartmental analysis. Considering the noncompartmental analysis, the mean maximum concentration of d-AMPH was almost 6-fold lower in plasma than in oral fluid and occurred at 3.8 and 4 hours, respectively, after LDX administration. LDX maximum concentration was reached at 1.2 and 1.8 hours after LDX oral administration for oral fluid and plasma, respectively, with a mean peak concentration almost 2-fold higher in plasma when compared with oral fluid. Elimination of d-AMPH from oral fluid and from plasma were similar, albeit for LDX elimination from oral fluid was slower even with lower concentrations than plasma. Detection occurred until 48 to 72 hours in plasma and oral fluid and until 120 hours in urine for d-AMPH. Whereas for LDX, detection could be done for up to 3, 5 and 12 hours in plasma, oral fluid and urine, respectively. Intact LDX and d-AMPH were detected in the three evaluated matrices. In compartmental analysis, the best model fit was observed for 1-compartment model for both analytes in plasma and in oral fluid. There was a correlation between oral fluid and plasma d-AMPH concentrations and between intact LDX/d-AMPH ratios along time in plasma as well as in oral fluid. The bioanalytical methods developed can be applied in different fields of knowledge in order to ensure the results of a positive screening analysis for AMPH. Nevertheless, for interpretation of situations in both screening and confirmation tests is necessary to combine the pharmacokinetic knowledge produced in this study, which shows if there is the possibility of detection in the analyzed matrix and for how long after the administration of LDX. This results aid in the differentiation from other AMPH derived drugs use and from illegal use, so that appropriate legal action and clinical management strategies for treatments and control of dependence be taken when necessary.